These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 11801521)

  • 21. Using intravenous diphenhydramine to minimize back pain associated with photodynamic therapy with verteporfin.
    Tornambe PE
    Arch Ophthalmol; 2002 Jun; 120(6):872. PubMed ID: 12049608
    [No Abstract]   [Full Text] [Related]  

  • 22. [Photodynamic therapy with Verteporfin in treatment of wet form ARMD - long term results].
    Vysloužilová D; Kolář P; Matušková V; Vlková E
    Cesk Slov Oftalmol; 2012 Jul; 68(3):98-101. PubMed ID: 23214457
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Verteporfin : a review of its use in the management of subfoveal choroidal neovascularisation.
    Keam SJ; Scott LJ; Curran MP
    Drugs; 2003; 63(22):2521-54. PubMed ID: 14609361
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month results of the DENALI study.
    Kaiser PK; Boyer DS; Cruess AF; Slakter JS; Pilz S; Weisberger A;
    Ophthalmology; 2012 May; 119(5):1001-10. PubMed ID: 22444829
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Photodynamic therapy with verteporfin combined with intravitreal injection of bevacizumab for exudative age-related macular degeneration.
    Aggio FB; Melo GB; Höfling-Lima AL; Eid Farah M
    Acta Ophthalmol Scand; 2006 Dec; 84(6):831-3. PubMed ID: 17083553
    [No Abstract]   [Full Text] [Related]  

  • 26. Light-activated agent approved for ocular disorder.
    Am J Health Syst Pharm; 2000 Jun; 57(11):1018, 1021. PubMed ID: 10876740
    [No Abstract]   [Full Text] [Related]  

  • 27. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: 5-year results of two randomized clinical trials with an open-label extension: TAP report no. 8.
    Kaiser PK;
    Graefes Arch Clin Exp Ophthalmol; 2006 Sep; 244(9):1132-42. PubMed ID: 16538452
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Photodynamic therapy with verteporfin: a new treatment in ophthalmology.
    Michels S; Schmidt-Erfurth U
    Semin Ophthalmol; 2001 Dec; 16(4):201-6. PubMed ID: 15513441
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Using contrast sensitivity to estimate the cost-effectiveness of verteporfin in patients with predominantly classic age-related macular degeneration.
    Bansback N; Davis S; Brazier J
    Eye (Lond); 2007 Dec; 21(12):1455-63. PubMed ID: 17086167
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study.
    Brown DM; Michels M; Kaiser PK; Heier JS; Sy JP; Ianchulev T;
    Ophthalmology; 2009 Jan; 116(1):57-65.e5. PubMed ID: 19118696
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of subfoveal choroidal neovascularisation in age related macular degeneration: focus on clinical application of verteporfin photodynamic therapy.
    Soubrane G; Bressler NM
    Br J Ophthalmol; 2001 Apr; 85(4):483-95. PubMed ID: 11264143
    [No Abstract]   [Full Text] [Related]  

  • 32. Verteporfin therapy combined with intravitreal triamcinolone in all types of choroidal neovascularization due to age-related macular degeneration.
    Augustin AJ; Schmidt-Erfurth U
    Ophthalmology; 2006 Jan; 113(1):14-22. PubMed ID: 16360209
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Photodynamic therapy with Visudyne in macular degeneration associated with subfoveal classical choroidal neovascularization].
    Soucek P; Boguzsaková J; Cihelková I
    Cesk Slov Oftalmol; 2002 Apr; 58(2):89-97. PubMed ID: 12046251
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Verteporfin photodynamic therapy combined with intravitreal bevacizumab for neovascular age-related macular degeneration.
    Kaiser PK; ; Boyer DS; Garcia R; Hao Y; Hughes MS; Jabbour NM; Kaiser PK; Mieler W; Slakter JS; Samuel M; Tolentino MJ; Roth D; Sheidow T; Strong HA
    Ophthalmology; 2009 Apr; 116(4):747-55, 755.e1. PubMed ID: 19243834
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: four-year results of an open-label extension of 2 randomized clinical trials: TAP Report No. 7.
    Bressler NM; Bressler SB; Haynes LA; Hao Y; Kaiser PK; Miller JW; Naor J; Potter MJ; Pournaras CJ; Reaves A; Rosenfeld PJ; Schmidt-Erfurth U; Slakter JS; Strong A; Vannier S
    Arch Ophthalmol; 2005 Sep; 123(9):1283-5. PubMed ID: 16157822
    [No Abstract]   [Full Text] [Related]  

  • 36. Model study of AREDS antioxidant supplementation of AMD compared to Visudyne: a dominant strategy?
    Trevithick J; Massel D; Robertson JM; Tomany S; Wall R
    Ophthalmic Epidemiol; 2004 Dec; 11(5):337-46. PubMed ID: 15590581
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinicopathological findings of choroidal neovascularisation following verteporfin photodynamic therapy.
    Gelisken F; Lafaut BA; Inhoffen W; Voelker M; Grisanti S; Bartz-Schmidt KU
    Br J Ophthalmol; 2004 Feb; 88(2):207-11. PubMed ID: 14736776
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of lesion size on photodynamic therapy with verteporfin of predominantly classic lesions in age related macular degeneration.
    Arias L; Pujol O; Berniell J; Rubio M; Roca G; Castillo L; Acebes E
    Br J Ophthalmol; 2005 Mar; 89(3):312-5. PubMed ID: 15722311
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: from clinical trials to clinical practice.
    Sickenberg M
    Semin Ophthalmol; 2001 Dec; 16(4):207-12. PubMed ID: 15513442
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Verteporfin for age-related macular degeneration.
    Messmer KJ; Abel SR
    Ann Pharmacother; 2001 Dec; 35(12):1593-8. PubMed ID: 11793628
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.